2062 related articles for article (PubMed ID: 11042650)
1. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
2. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
4. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
5. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
6. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
7. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kröger N; Krüger W; Wacker-Backhaus G; Hegewisch-Becker S; Stockschläder M; Fuchs N; Rüssmann B; Renges H; Dürken M; Bielack S; de Wit M; Schuch G; Bartels H; Braumann D; Kuse R; Kabisch H; Erttmann R; Zander AR
Bone Marrow Transplant; 1998 Dec; 22(11):1029-33. PubMed ID: 9877263
[TBL] [Abstract][Full Text] [Related]
8. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
9. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
10. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
[TBL] [Abstract][Full Text] [Related]
12. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
[TBL] [Abstract][Full Text] [Related]
14. The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen.
Pediatr Blood Cancer; ; . PubMed ID: 16425264
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
